small molecule

ZEVTERA

CEFTOBIPROLE MEDOCARIL SODIUM

Loss of exclusivityApril 2034FDA regulatory exclusivity expiry

CompanyISTX LLC

Drug detail

Brand name	ZEVTERA
Active ingredient	CEFTOBIPROLE MEDOCARIL SODIUM
Strength	667MG/VIAL
Dosage form	POWDER
Route	INTRAVENOUS
Modality	Small molecule
FDA approval	April 2024
Marketing status	RX

Regulatory exclusivity

Code	Expires
GAIN	April 2034
NCE	April 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.